Cipher Pharmaceuticals Company Profile (TSE:DND)

About Cipher Pharmaceuticals (TSE:DND)

Cipher Pharmaceuticals logoCipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

Industry, Sector and Symbol:
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 44.75%
  • Return on Equity: 113.74%
  • Return on Assets: 26.78%
 

Frequently Asked Questions for Cipher Pharmaceuticals (TSE:DND)

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the Tornton Stock Exchange (TSX) under the ticker symbol "DND."

Who are some of Cipher Pharmaceuticals' key competitors?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the folowing people:

  • John D. Mull M.D., Chairman of the Board
  • Robert D. Tessarolo, President, Chief Executive Officer
  • Stephen L. Lemieux CPA, Chief Financial Officer, Secretary
  • Ralph Bohrer, President and General Manager of US Business
  • Joan Chypyha, President, General Manager - Canada
  • Joseph Pecora, President and General Manager - USA
  • Lorne Markowitz, Vice President of Sales and Marketing
  • Linda Melanie Angaritis, Vice President - Global Regulatory Compliance and Quality
  • Louise Blythe, Vice President - Regulatory Affairs
  • Lynne Cheryl Bulger, Vice President - Medical and Clinical Affairs

How do I buy Cipher Pharmaceuticals stock?

Shares of Cipher Pharmaceuticals and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of Cipher Pharmaceuticals stock can currently be purchased for approximately C$14.89.


MarketBeat Community Rating for Cipher Pharmaceuticals (TSE DND)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  28 (Vote Outperform)
Underperform Votes:  26 (Vote Underperform)
Total Votes:  54
MarketBeat's community ratings are surveys of what our community members think about Cipher Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cipher Pharmaceuticals (TSE:DND) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cipher Pharmaceuticals (TSE:DND)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Cipher Pharmaceuticals (TSE:DND)
Earnings by Quarter for Cipher Pharmaceuticals (TSE:DND)
Earnings History by Quarter for Cipher Pharmaceuticals (TSE DND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2014C$0.18C$0.17ViewN/AView Earnings Details
5/5/2014C$0.19C$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cipher Pharmaceuticals (TSE:DND)
Current Year EPS Consensus Estimate: $0.47 EPS

Dividends

Dividend History for Cipher Pharmaceuticals (TSE:DND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cipher Pharmaceuticals (TSE:DND)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Cipher Pharmaceuticals (TSE:DND)
Latest Headlines for Cipher Pharmaceuticals (TSE:DND)
Source:
DateHeadline
finance.yahoo.com logoCPHR: Total Revenue Grew 28% in Third Quarter of 2015
finance.yahoo.com - September 14 at 3:45 PM
finance.yahoo.com logoCPHR: Total Revenue Grew 28% in Third Quarter of 2015
finance.yahoo.com - November 5 at 10:40 AM
finance.yahoo.com logoCipher Pharmaceuticals posts 1Q profit
finance.yahoo.com - May 13 at 7:30 AM

Social

Chart

Cipher Pharmaceuticals (DND) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff